Spartalizumab - Novartis Oncology

Drug Profile

Spartalizumab - Novartis Oncology

Alternative Names: PDR 001

Latest Information Update: 02 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Dana-Farber Cancer Institute; Novartis; Novartis Oncology; Palobiofarma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Diffuse large B cell lymphoma; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; Breast cancer; Cancer; Colorectal cancer; Hepatocellular carcinoma; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Ovarian cancer; Pancreatic cancer; Renal cancer

Most Recent Events

  • 18 Jun 2018 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT02403193) (Palobiofarma pipeline, June 2018)
  • 12 Jun 2018 Phase-I clinical trials in Pancreatic cancer, Renal cancer and Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT03549000)
  • 01 Jun 2018 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASC0-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top